Casdin Partners于12月3日以1.44美元的价格购买了标准生物工具的75K股,将其股份增加到71.95M股。 Casdin Partners bought 75K shares of Standard BioTools at $1.44 on Dec. 3, boosting its stake to 71.95M shares.

Casdin Partners Master Fund，Standard BioTools（LAB）的董事，于2025年12月3日以每股1.44美元的价格购买了75,000股，继11月至12月初的近期超过950万股买入之后。 Casdin Partners Master Fund, a director of Standard BioTools (LAB), purchased 75,000 shares on December 3, 2025, at $1.44 per share, adding to recent buys totaling over 9.5 million shares in November and early December. 根据证交会的申报,基金目前持有约7 195万股,价值1.036亿美元。 The fund now holds about 71.95 million shares, valued at $103.6 million, according to SEC filings. 库存于12月4日以1.44美元关闭,市场上限为5.5378亿美元。 The stock closed at $1.44 on December 4 with a market cap of $553.78 million. 分析师前景喜忧参半,“降价”评级一致,平均价格目标为1.35美元。 Analysts have a mixed outlook, with a consensus "Reduce" rating and a $1.35 average price target.